XML 61 R41.htm IDEA: XBRL DOCUMENT v3.25.0.1
STOCK-BASED AWARDS (Tables)
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity A summary of stock option activity for the year ended December 31, 2024 was as follows:
Outstanding Options
Number of OptionsWeighted Average Exercise PriceWeighted-Average Remaining Contractual Term
Intrinsic Value
(in thousands)
Balance as of December 31, 2023
32,911,135 $1.99 5.5$91,785 
Options granted
232,177 3.99 
Options exercised
(4,513,606)1.08 
Options canceled
(1,735,603)7.01 
Balance as of December 31, 2024
26,894,103 $1.84 4.4$48,886 
Options vested and exercisable as of December 31, 2024
24,696,617 $1.37 4.2$48,883 
Schedule of Stock Option Valuation Assumptions A summary of the weighted-average assumptions the Company utilized to record compensation expense for stock options granted during the years ended December 31, 2024 and 2023 was as follows:
December 31,
2024		December 31,
2023
Volatility
85.0 %83.9 %
Expected term (in years)5.25.0
Risk-free interest rate4.3 %4.1 %
Expected dividends— %— %
Schedule of Restricted Stock Units Activity
A summary of RSUs activity for the year ended December 31, 2024 was as follows:
Restricted Stock Units
Time-Based SharesPerformance-Based SharesTotal SharesWeighted-Average Grant-Date Fair Value
Balance as of December 31, 2023
54,699,739 9,305,825 64,005,564 $10.90 
Granted94,696,162 14,188,690 108,884,852 2.86 
Vested(46,298,088)(1,884,410)(48,182,498)7.73 
Cancelled/Forfeited(15,128,805)(5,613,644)(20,742,449)6.48 
Balance as of December 31, 2024
87,969,008 15,996,461 103,965,469 $4.83 
Schedule of Performance-Based RSUs The fair value of these performance-based RSUs was measured on the grant date, March 27, 2021, using a Monte Carlo simulation model, with the following assumptions:
Weighted average volatility60.0 %
Expected term (in years)5.0
Risk-free interest rate0.9 %
Expected dividends— %
Schedule of Stock-Based Compensation Expense
Total employee and nonemployee stock-based compensation expense for the years ended December 31, 2024, 2023 and 2022, was classified in the consolidated statements of operations and comprehensive loss as follows (in thousands):
Year Ended December 31,
202420232022
Cost of revenue$4,335 $3,590 $41,753 
Research and development172,190 137,703 151,549 
Selling, general and administrative110,827 117,433 230,198 
Restructuring charges
(1,480)(1,443)— 
Total$285,872 $257,283 $423,500